This issue of Hematology/Oncology Clinics of North America, devoted to Multiple Myeloma, is edited by Dr. Kenneth C. Anderson. Articles in this issue include: Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma; Diagnosis and Risk Stratification in Myeloma; Treatment of Newly Diagnosed Transplant Eligible Patients; Treatment of Newly Diagnosed Transplant Ineligible Patients; Treatment of Relapsed/Refractory Myeloma; Maintenance Therapy; Novel Targeted Therapies; Novel Immune-based Therapies; Allotransplantation in Myeloma; and Waldenstrom’s Macroglobulinemia.
1. Cover image - p. 1 2. Title page - p. 2 3. Table of Contents - p. 3 4. Contributors - p. 4 5. HEMATOLOGY/ONCOLOGY CLINICS OF NORTH AMERICA - p. 5 6. Preface: Multiple Myeloma - p. 6 7. Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma - p. 7 8. Diagnosis and Risk Stratification in Multiple Myeloma - p. 16 9. Treatment of Transplant-Eligible Patients with Multiple Myeloma in 2014 - p. 26 10. Frontline Therapy for Patients with Multiple Myeloma not Eligible for Stem Cell Transplantation - p. 34 11. Maintenance Therapy for Multiple Myeloma - p. 39 12. Relapsed and Refractory Multiple Myeloma - p. 52 13. Allogeneic Stem Cell Transplantation for Multiple Myeloma - p. 68 14. Novel Targeted Agents in the Treatment of Multiple Myeloma - p. 75 15. Immunotherapy Strategies in Multiple Myeloma - p. 84 16. Waldenström Macroglobulinemia - p. 94 17. Index - p. 109
No hay muestra disponible
No hay ficha técnica disponible
This issue of Hematology/Oncology Clinics of North America, devoted to Multiple Myeloma, is edited by Dr. Kenneth C. Anderson. Articles in this issue include: Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma; Diagnosis and Risk Stratification in Myeloma; Treatment of Newly Diagnosed Transplant Eligible Patients; Treatment of Newly Diagnosed Transplant Ineligible Patients; Treatment of Relapsed/Refractory Myeloma; Maintenance Therapy; Novel Targeted Therapies; Novel Immune-based Therapies; Allotransplantation in Myeloma; and Waldenstrom’s Macroglobulinemia.
1. Cover image - p. 1 2. Title page - p. 2 3. Table of Contents - p. 3 4. Contributors - p. 4 5. HEMATOLOGY/ONCOLOGY CLINICS OF NORTH AMERICA - p. 5 6. Preface: Multiple Myeloma - p. 6 7. Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma - p. 7 8. Diagnosis and Risk Stratification in Multiple Myeloma - p. 16 9. Treatment of Transplant-Eligible Patients with Multiple Myeloma in 2014 - p. 26 10. Frontline Therapy for Patients with Multiple Myeloma not Eligible for Stem Cell Transplantation - p. 34 11. Maintenance Therapy for Multiple Myeloma - p. 39 12. Relapsed and Refractory Multiple Myeloma - p. 52 13. Allogeneic Stem Cell Transplantation for Multiple Myeloma - p. 68 14. Novel Targeted Agents in the Treatment of Multiple Myeloma - p. 75 15. Immunotherapy Strategies in Multiple Myeloma - p. 84 16. Waldenström Macroglobulinemia - p. 94 17. Index - p. 109
No hay muestra disponible
No hay ficha técnica disponible
